Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study.
Singh JA.
Clin Rheumatol. 2021 Jul;40(7):3007-3014. doi: 10.1007/s10067-021-05715-6. Epub 2021 Mar 30.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Hallucinogen Use Disorders.
Hardaway R, Schweitzer J, Suzuki J.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):489-96. doi: 10.1016/j.chc.2016.03.006. Epub 2016 Apr 18.
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L.
Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948.
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD.
Psychiatry Res. 2023 Nov;329:115531. doi: 10.1016/j.psychres.2023.115531. Epub 2023 Oct 11.
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky TG, Jagodnik KM, Barsic R, Antonio JH, Bonanno PA, MacLeod C, Pierce C, Carney H, Morrison MT, Saylor C, Danias G, Lepow L, Yehuda R.
Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147.
Psychedelics.
Kelmendi B, Kaye AP, Pittenger C, Kwan AC.
Curr Biol. 2022 Jan 24;32(2):R63-R67. doi: 10.1016/j.cub.2021.12.009.
Towards an understanding of psychedelic-induced neuroplasticity.
Calder AE, Hasler G.
Neuropsychopharmacology. 2023 Jan;48(1):104-112. doi: 10.1038/s41386-022-01389-z. Epub 2022 Sep 19.
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937.
Psychedelic-inspired approaches for treating neurodegenerative disorders.
Saeger HN, Olson DE.
J Neurochem. 2022 Jul;162(1):109-127. doi: 10.1111/jnc.15544. Epub 2021 Dec 5.
